The objective of this article is to offer a personal perspective on managing melancholia by interpreting both the limited salient evidence base and offering clinical observations.
Conclusions:
It is suggested that medication needs to be prioritised, that not all antidepressants are equally potent for those with melancholia and that as response to a single antidepressant alone (especially a narrow-spectrum one) is low, management commonly requires broader-spectrum antidepressant drugs and augmentation strategies.
ParkerG.Diagnosing melancholic depression: some personal perspectives. Australas Psychiatry2017; 25: 21–24.
2.
BoboWVChenHTrivedi. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord2011; 133: 467–476.
3.
BrownWA.Treatment response in melancholia. Acta Psychiatr Scand2007; 115: 125–129.
4.
ParkerGBlanchBPatersonA. The superiority of antidepressant medication to cognitive behavior therapy in melancholic depressed patients: a 12-week single-blind randomized study. Acta Psychiatr Scand2013; 128: 271–281.
5.
PerryPJ.Pharamacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus serotonin reuptake inhibitor antidepressants. J Affect Disord1996; 39: 1–6.
6.
McGrathPJKhanAYTrivediMH. Response to a selective reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psych2008; 69: 1847–1855.
7.
ParkerG.Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychitr Scand2002; 106: 168–170.
8.
ParkerG.Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders. Int Clin Psychopharm2003; 17: 87–89.
9.
ParkerGBrotchieHMcClureG. Psychostimulants for managing unipolar and bipolar treatment-resistant melancholic depression: a medium term evaluation of cost benefits. J Affect Disord2013; 151: 360–364.
